Donor leukocyte infusion (DLI) alone has very limited efficacy for patients with acute lymphoblastic leukemia (ALL) who have relapsed after allogeneic bone marrow transplantation (BMT). We, therefore, prospectively tested the efficacy of cytoreductive chemotherapy (intermediate-dose cytarabine þ idarubicin þ etoposide) followed immediately by G-CSF-primed DLI (Chemo-DLI) in 10 relapsed ALL patients after allogeneic BMT. Seven achieved complete remission (CR) at a median of 25 days (19-73 days) after DLI. Of these seven CR patients, only one remains alive in CR 907 days after DLI. Two CR patients died in CR of graft-versus-host disease. The remaining four CR patients relapsed at a median of 153 days (120-991 days) after DLI. One is alive with leukemia at post-DLI day 1217. The median survival duration after DLI was 175 days (15-1217 days). In summary, although Chemo-DLI for relapsed ALL after allogeneic BMT induced a relatively high CR rate, durable remissions were rare. Although our data should be interpreted cautiously considering the small number of patients, these results suggest that poor outcome of DLI in relapsed ALL may be primarily due to intrinsic resistance to graft-versus-leukemia effect rather than to the rapid pace of the disease. For patients with acute lymphoblastic leukemia (ALL) receiving allogeneic bone marrow transplantation (BMT), relapse remains the major cause of treatment failure and is associated with a very poor prognosis. The optimal salvage treatment for patients with ALL who relapse after allogeneic BMT has not yet been established, since most therapies are of limited benefit. While reinduction chemotherapy can induce remission in about 40-60% of patients, most of these patients eventually relapse and die of uncontrolled leukemia, with a 3-year disease-free survival (DFS) rate of less than 10%.
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For patients with acute lymphoblastic leukemia (ALL) receiving allogeneic bone marrow transplantation (BMT), relapse remains the major cause of treatment failure and is associated with a very poor prognosis. The optimal salvage treatment for patients with ALL who relapse after allogeneic BMT has not yet been established, since most therapies are of limited benefit. While reinduction chemotherapy can induce remission in about 40-60% of patients, most of these patients eventually relapse and die of uncontrolled leukemia, with a 3-year disease-free survival (DFS) rate of less than 10%. [1] [2] [3] [4] A second BMT results in long-term event-free survival in only 10-20% of patients with relapsed ALL. [5] [6] [7] However, even these poor results may be an overestimate because only a small proportion of relapsed patients is suitable for second BMT, and hence the results may reflect the positively biased outcome of a highly selected group of patients. Only 7-20% of patients has been reported to reach the stage of a second BMT after relapse according to the performance and remission status after salvage chemotherapy. 2, 8 Moreover, second BMT is associated with extremely high treatment-related mortality, ranging from 40% to 50%. [6] [7] [8] Another approach to the treatment of ALL patients who relapse after allogeneic BMT is donor leukocyte infusion (DLI), which may induce a graft-versus-leukemia (GVL) effect. DLI has been shown to be highly effective in patients with chronic myelogenous leukemia (CML) who relapse into the chronic phase, achieving complete and durable remission in 70-80% of these patients. 9, 10 In contrast, DLI for relapsed ALL has been much less effective. Although there have been many case reports showing that patients with ALL respond to DLI, [11] [12] [13] [14] [15] [16] [17] [18] [19] analyses of larger patient groups in multicenter registry studies have shown that DLI alone has limited efficacy in ALL, with one of 12 patients in the European registry study 20 and two of 15 in the North American registry study 21 reported to achieve CR with DLI alone. In the Japanese registry study, DLI alone induced CR in six of 24 patients, but only one patient maintained CR for 1 year. 22 The limited efficacy of DLI alone for relapsed ALL may be due in part to the diverse immune escape mechanisms of leukemic cells from GVL, [23] [24] [25] [26] [27] [28] or to the rapid proliferation rate of leukemic cells coupled with the high-leukemic cell burden at the time of relapse, thus preventing the development of a clinically evident GVL effect. Since a GVL effect of DLI typically requires several weeks or months to become clinically apparent, 10, 29, 30 it would be reasonable to attempt cytoreductive chemotherapy before DLI in patients with rapidly advancing diseases such as ALL, thus allowing sufficient time for the development of the GVL effect. Despite the theoretical benefit of cytoreductive chemotherapy before DLI, this approach has been rarely attempted in the treatment of relapsed ALL after allogeneic BMT, although the outcomes reported by some registry studies were poor. 20, 21 For example, in the North American registry study, only one of 29 patients who received DLI as consolidation of remission or in the nadir period after chemotherapy achieved ongoing remission, 21 and in the European registry study, only one of 10 patients achieved CR that lasted for 14 months following concomitant use of chemotherapy and DLI. 20 These findings are, however, limited by the retrospective nature of the studies, heterogeneous treatment schemes, and the small numbers of patients included. Thus, there is a need for prospective studies evaluating the efficacy of chemotherapy followed by DLI (Chemo-DLI) in ALL relapsing after allogeneic BMT.
We previously reported preliminary results of a prospective study evaluating the efficacy of Chemo-DLI in patients with relapsed acute leukemia, including five patients with ALL, after allogeneic BMT. 31 We reported that, although four of five patients achieved CR with this approach, all the patients eventually died of relapsed leukemia or treatment-related complications. The present study updates our previous findings and reports our experience with Chemo-DLI in a larger cohort of patients with relapsed ALL following allogeneic BMT.
Patients and methods

Patient eligibility
Patients were eligible for treatment if they had undergone allogeneic BMT for ALL and subsequently relapsed. To be included, patients were required to have sufficient cardiac function (ejection fraction X40%), a creatinine level of less than 2.0 mg/dl, a bilirubin level of less than 2.0 mg/dl, a liver transaminases level lower than three times the upper limit of the normal range, and Karnofsky performance status equal to or over 70. The study protocol was approved by the Institutional Review Board of the Asian Medical Center. Written informed consent was obtained from each patient and donor. Patients were enrolled in this prospective study between January 1998 and February 2002. During the study period, 13 patients with ALL relapsed following allogeneic BMT. Three of these patients were excluded from this study, two for poor performance status, and one due to the original unrelated marrow donor's personal situation that precluded donation of G-CSF-primed leukocytes. Thus, the 10 remaining patients were enrolled in the study.
Initial BMT procedure
Detailed procedures for initial transplantation have been described previously. 32 At the time of initial BMT, seven patients were in CR (six with first CR; one with second CR), and three had untreated relapses (one with first relapse; two with second relapse). Three patients who were not in CR at the time of BMT achieved CR after BMT. All patients received Bu-Cy (busulfan 4 mg/kg/day on days À7 to À4 and cyclophosphamide 60 mg/kg/day on days À3 to À2) as a preparative regimen. Eight patients received bone marrow grafts from HLA-identical siblings, whereas two patients (UPN 110 and 118) received a bone marrow graft from an HLA-matched unrelated donor. None of the bone marrow grafts was T-cell depleted. Graft-versus-hostdisease (GVHD) prophylaxis consisted of cyclosporine (1.5 mg/kg intravenously every 12 h starting on day À1, switching to oral administration when feasible) plus a short-course of methotrexate (15 mg/m 2 intravenously on day 1, and 10 mg/m 2 intravenously on days 3, 6, and 11). In the absence of GVHD, cyclosporine was tapered from day 60 until day 180. After initial BMT, one patient (UPN 118) developed acute GVHD of grade III at post-BMT day 7 and progressed to extensive chronic GVHD at day 96. Two other patients developed de novo chronic GVHD, one (UPN 110) with limited disease at day 500 and one (UPN 73) with extensive disease at day 203. Owing to active chronic GVHD, all these three patients were on immunosuppressive agents at the time of relapse after BMT.
Treatment of relapse after allogeneic BMT
The first day of DLI was designated day 0. The induction chemotherapy regimen, administered from day À7 to day À2, consisted of cytarabine (1 g/m 2 /day continuous intravenous infusion on days À7 to À2), idarubicin (12 mg/m 2 / day intravenous infusion on days À7 to À5), and etoposide (150 mg/m 2 /day intravenous infusion over 5 h on days À7 to À5). Each original bone marrow donor was administered G-CSF (10 mg/kg/day subcutaneously from day À3 to 0), and their peripheral blood mononuclear cells, including lymphocytes and CD34 þ cells, were collected on days 0 and 1 of DLI and infused into the recipient on the same days to induce a GVL effect and to minimize marrow aplasia after chemotherapy. Patients subsequently received G-CSF 450 mg/day intravenously from day 5 until their absolute neutrophil counts were greater than 3000/ml. Patients given immunosuppressive agents for the prophylaxis or treatment of GVHD at the time of relapse after initial BMT were discontinued from these immunosuppressive agents before induction chemotherapy. No post-DLI GVHD prophylaxis was administered. Acute and chronic GVHD were graded according to established criteria. 33, 34 Grade II-IV acute GVHD or extensive chronic GVHD occurring after DLI was treated with corticosteroid plus other immunosuppressive agent(s) such as cyclosporine, tacrolimus or mycophenolate. Limited chronic GVHD was treated with cyclosprorine and/or corticosteroid when symptoms or signs of GVHD were progressive during observation without treatment. Bone marrow examination of patients showing full hematologic recovery in peripheral blood was performed to evaluate their remission status after Chemo-DLI. Patients presenting with extramedullary leukemia at relapse after initial BMT were evaluated by physical examination and appropriate radiologic methods. CR was defined as cellular marrow containing less than 5% blasts, no evidence of extramedullary leukemia, and peripheral neutrophil and platelet counts of at least 1500/ml and 100 000/ml, respectively.
Evaluation of hematopoietic chimerism
Since December 1997, post-BMT, and post-DLI hematopoietic chimerism have been prospectively evaluated in patients' peripheral blood mononuclear cells using the polymerase chain reaction to amplify short tandem repeats or amelogenin loci, as previously described. 35, 36 
Statistical analysis
Overall survival (OS) was measured from the date of DLI to the date of death or last follow-up, and was plotted using the Kaplan-Meier method.
Results
Patient characteristics
The clinical characteristics of the patients are shown in Table 1 , who relapsed initially at an extramedullary site (left breast) without bone marrow involvement, achieved CR after application of local radiation therapy to the extramedullary relapse site. Subsequently, however, this patient relapsed at other extramedullary sites such as multiple bones, and local radiation was delivered to the involved sites. At 11 months after the first documentation of relapse after BMT, this patient experienced relapses in the bone marrow along with the right breast, and received Chemo-DLI 350 days after initial isolated extramedullary relapse.
Response and overall clinical course
Data regarding the clinical course after Chemo-DLI are summarized in Table 2 110) is alive with disease at post-DLI day 1217. All 4 relapsers had experienced post-DLI acute and/or chronic GVHD before relapse. For all patients, the median survival duration after DLI was 175 days (range, 15-1217 days). Four patients were alive 1 year after DLI, and 2 were alive 2 years after DLI, respectively, making the 1-and 2-year OS rates 40% (95% CI, 10-70%) and 20% (95% CI, 0-45%), respectively ( Figure 1 ).
Hematopoietic chimerism after Chemo-DLI
We were unable to evaluate post-DLI hematopoietic chimerism in three patients, two who died within 1 month Chemo-DLI for relapsed ALL after allogeneic BMT S-J Choi et al of DLI and one other patient. The remaining seven patients, including one (UPN 3) who did not achieve CR with Chemo-DLI but did not show leukemic cells in peripheral blood at the time of chimerism analysis, all showed complete donor chimerism 1 month after DLI (Table 2) .
Treatment-related toxicities and death
All patients experienced severe myelosuppression, with lowest neutrophil count less than 500/ml and lowest platelet count less than 20 000/ml. All patients achieved neutrophil counts over 500/ml at a median of 11.5 days (range, 9-18 days) after DLI. Omitting the two early deaths, eight patients achieved a platelet count over 20 000/ml without transfusion support at a median of 18 days (range, 10-28 days) after DLI. All patients experienced febrile neutropenia necessitating treatment with antimicrobials. Within 100 days after DLI, four patients experienced pneumonia, three experienced bacteriologically documented septicemia, two experienced CMV antigenemia, and one experienced herpes zoster infection.
Seven of eight assessable patients developed acute GVHD at a median of 22 days after DLI (range, 10-53 days), one with grade I, two with grade II, three with grade III, and one with grade IV. Three of seven assessable patients developed extensive chronic GVHD, at 63, 226, and 235 days after DLI. Two patients (UPN 47 and UPN 93) died of GVHD in the status of CR at post-DLI days 273 and 61, respectively. Among the six patients with grades II-IV acute GVHD and/or extensive chronic GVHD, four (UPN 47, UPN 60, UPN 73, and UPN 93) received immunosuppressive agents until the time of their death for their GVHD being not in remission; one patient (UPN 71), whose GVHD was in remission, discontinued immunosuppressive agents on the day post-DLI relapse was documented; and one patient (UPN 110), who experienced complete resolution of acute GVHD, discontinued immunosuppressive agents on day 160.
Of the three patients not achieving CR, one (UPN 3) died with persistent leukemia at 425 days after DLI, and the other two (UPN 40 and UPN 118) died due, at least in part, to treatment-related toxicities. since bone marrow status after Chemo-DLI was not evaluated due to early death (patient UPN 40 on post-DLI day 15 and patient UPN 118 on post-DLI day 22), we were unable to determine whether the major cause of death in these two patients was treatment-related toxicity or resistant leukemia. However, there was no clinical evidence of leukemia in their peripheral blood or extramedullary sites at the time of death. The proximate causes of death in these two patients were pneumonia. On this assumption, there were four treatment-related deaths, including the two patients who died in CR from GVHD.
Discussion
Our study showed that DLI, even with the concomitant use of chemotherapy, has limited benefit in patients with ALL relapsing after allogeneic BMT. Using Chemo-DLI, we Table 2 Details of the clinical course after chemotherapy followed by donor leukocyte infusion found that CR could be achieved in seven of 10 patients. Although it is difficult to dissect the net effect of chemotherapy from that of DLI, this relatively high CR rate seems to be mainly the result of chemotherapy, inasmuch as DLI alone was found to yield a poor response rate in previous registry studies. 20, 21 Despite the relatively high CR rate, however, the quality of the CR achieved was not good in most cases. Of the five CR patients who did not die of toxicity, four eventually relapsed, even with the occurrence of post-DLI GVHD. Only two patients achieved CR of 2 years or more, and only one still remains alive in CR 907 days after DLI. Although our data should be interpreted cautiously, due to the limited number of patients, these findings suggest that the poor outcome of Chemo-DLI in relapsed ALL after allogeneic BMT may be primarily due to the intrinsic resistance to the GVL effect rather than to the rapid pace of the disease.
Our results support the findings of several retrospective studies, suggesting that the GVL effect of DLI for ALL may be weaker than that for acute myeloid leukemia (AML). We previously reported results of the effect of Chemo-DLI in patients with AML who relapsed after allogeneic BMT. 37 Except for the eligibility criterion for the underlying disease (AML vs ALL), the designs of the two studies were identical, including the chemotherapy regimen before DLI, use of G-CSF-primed DLI, timing of DLI and no post-DLI GVHD prophylaxis. In our AML study, Chemo-DLI induced a relatively high-CR rate of 63% and durable remissions in a considerable proportion of CR patients, with a 2-year DFS of 44%. The outcomes in our ALL study reported here, however, were poorer, especially for DFS. The poor GVL effect of DLI in ALL may be explained by the diverse immune escape mechanisms of leukemic cells, including the downregulation of HLA molecules, 23 defects in presentation of antigenic peptides, 24 deficient expression of costimulatory molecules, 25, 26 induction of T-cell anergy to alloantigen, 26 secretion by leukemic cells of cytokines that inhibit activated lymphocytes, 27 and FAS ligand expression by leukemic cells. 28 However, it remains unclear why the GVL effect of DLI in ALL is weaker than that in myeloid leukemias, although it has been suggested that the better response of myeloid leukemia to DLI, compared with lymphoid leukemia, may be due to the direct presentation of leukemia antigens to donor T cells by myeloid leukemia-derived dendritic cells. 9 This hypothesis has been supported by the finding that dendritic cells in CML display the bcr/abl translocation, as well as by the observation that dendritic cells of leukemia origin stimulate allogeneic T lymphocytes and induce cytotoxic T lymphocytes. 38, 39 In AML, leukemic dendritic cells may be differentiated from leukemic blasts by culture with GM-CSF and IL-4. [40] [41] [42] Currently, however, the clinical relevance of this issue has yet to be established.
Although GVL effect of DLI for ALL is generally weak, it would be meaningful in a subset of patients considering the observation that three patients (UPN 47, UPN 87, UPN 110) had similar or longer remission duration lasting 9, 30 þ , and 33 months compared with initial post-BMT remissions of 6, 39, and 23 months, respectively. To improve the outcome after DLI for relapsed ALL, it would be fundamental to understand more about the mechanisms of the GVL effect and the immune escape mechanisms of leukemic cells. At present, several approaches could be considered to improve the outcomes of DLI for relapsed ALL. One potential way to enhance the GVL effect of DLI may be to use biologic response modifiers such as interleukin-2 (IL-2), which has been shown to induce the activation and proliferation of both T and NK cells. Although experience with the combination of IL-2 plus DLI for the treatment of leukemia relapse after allogeneic BMT is limited, several studies reported its feasibility and potential benefit in a variety of hematologic malignancies including ALL. 13, 43, 44 Another potential approach is adoptive immunotherapy using ex vivo-generated cytotoxic donor T lymphocytes stimulated by donor dendritic cells pulsed with minor histocompatibility antigens or leukemic lysates. 45, 46 In addition, it may also be important to minimize the leukemic cell burden before the application of DLI, since the GVL effect of DLI would be more effective when the disease is minimal. To achieve this goal, several cycles of chemotherapy and/or addition of new therapeutic agents into usual chemotherapy regimen could be tried before and/or after DLI with careful monitoring of minimal residual disease. For example, anti-CD20 monoclonal antibody (rituximab) could be used in conjunction with cytotoxic chemotherapy for the treatment of relapsed CD20-positive B-lineage ALL. In support of this hypothesis, several case reports have shown that rituximab can induce molecular remissions in ALL with minimal residual disease. 47, 48 In summary, although Chemo-DLI for relapsed ALL after allogeneic BMT could achieve a relatively high CR rate, durable remissions were rare. Although our data should be interpreted cautiously, due to the limited number of patients, the results of our study suggest that the poor outcome of Chemo-DLI in relapsed ALL after allogeneic BMT may be primarily due to the intrinsic resistance to the GVL effect rather than to the rapid pace of the disease.
